Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.36 |
| ▸ | VEGFA | P15692 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.33 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.33 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14809136 | 0.92 | MAPT (0.37) | EGLN1VEGFAMAPTTP53KMT2A | |
| SCHEMBL14810102 | 0.92 | MAPT (0.38) | EGLN1VEGFAMAPTTP53KMT2A | |
| SCHEMBL14809540 | 0.87 | EGLN1 (0.39) | EGLN1VEGFAMAPTTP53KMT2A | |
| SCHEMBL14809484 | 0.86 | KDM4E (0.33) | ALDH1A1KDM4E | |
| SCHEMBL14809836 | 0.85 | MAPT (0.36) | MAPTTP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL14810583 | 0.85 | MEN1 (0.37) | EGLN1MAPTTP53KMT2AMEN1 | |
| SCHEMBL14810111 | 0.84 | MAPT (0.39) | EGLN1VEGFAMAPTTP53ALDH1A1 | |
| SCHEMBL14809456 | 0.84 | MAPT (0.38) | MAPTTP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL14810785 | 0.83 | MAPK8 (0.38) | KMT2AMEN1ALDH1A1MAPK8LMNA | |
| SCHEMBL16252245 | 0.83 | EP300 (0.36) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2757887-B1 | PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV | VIIV HEALTHCARE UK LTD (GB) | 2017-04-26 | — | — | EP | disclosed |
| EP-2757887-B1 | PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV | VIIV HEALTHCARE UK LTD (GB) | 2017-04-26 | — | — | EP | disclosed |
| US-9012642-B2 | Pyrrolopyridinone compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-04-21 | — | — | US | disclosed |
| US-9012642-B2 | Pyrrolopyridinone compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-04-21 | — | — | US | disclosed |
| US-9012642-B2 | Pyrrolopyridinone compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-04-21 | — | — | US | disclosed |
| US-20140343092-A1 | Pyrrolopyridinone Compounds And Methods For Treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2014-11-20 | — | — | US | disclosed |
| US-20140343092-A1 | Pyrrolopyridinone Compounds And Methods For Treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2014-11-20 | — | — | US | disclosed |
| US-20140343092-A1 | Pyrrolopyridinone Compounds And Methods For Treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2014-11-20 | — | — | US | disclosed |
| EP-2757887-A1 | PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV | VIIV Healthcare UK Limited (GB) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013043553-A1 | PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV | GLAXOSMITHKLINE LLC (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013043553-A1 | PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV | GLAXOSMITHKLINE LLC (US) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343092-A1 | Pyrrolopyridinone Compounds And Methods For Treating HIV | DHPS, PRNP, TYMP | EGLN1 425/4885VEGFA 4404/4885MAPT 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.